WHO First Dengue Vaccine Position Paper Published

Dengue News Alert by the Dengue Vaccine Intitiative

View this email in yourbrowser

Dengue News AlertWHO First Dengue Vaccine Position Paper Published

Today, the World Health Organization (WHO) published in the Weekly Epidemiological Record its first Position Paper on a dengue vaccine, based on the available evidence of CYD-TDV or Dengvaxia®, the only dengue vaccine to have received regulatory approval. Starting in December of 2015, Dengvaxia® has been approved by the regulatory authorities of Mexico, the Philippines, Brazil, El Salvador, Paraguay and Costa Rica. WHO recommends that countries should consider introduction of the dengue vaccine Dengvaxia® only in geographic settings (national or subnational) where epidemiological data indicate a high burden of disease. Read more WHO recommendations here.

The WHO’s position papers seek to provide guidance to countries on health policy matters, such as vaccines against diseases that have an international public health impact. They are intended for use primarily by national public health officials, managers of immunization programs and national dengue control programs. The papers have been reviewed by external experts and WHO staff, and are reviewed and endorsed by the WHO Strategic Advisory Group of Experts on Immunization (SAGE), which on April 15, 2016, issued recommendations on the use of Dengvaxia®.

Dengue vaccines have been under development since the 1940s, but due to the limited appreciation of the global burden of dengue, interest languished for much of the 20th century. However, recent years have seen a dramatic increase in dengue vaccine progress. Today several vaccine candidates are undergoing clinical development, some of which are in advanced stages.

For an overview of the Position Paper you can access our blog post here.

Resources

• WHO dengue vaccine PositionPaper
• WHO summary of dengue vaccinePosition Paper
• Dengue vaccines currently inclinical development
• What is the process behindvaccine registration and policies for use?
• International dengue vaccinecommunication and advocacy: challenges and way forward
• Points for consideration fordengue vaccine introduction
• Financing dengue vaccineintroduction in the Americas: challenges and opportunities
• Edging closer towards the goalof a dengue vaccine
• DVI statements on denguevaccine development

About the Dengue Vaccine Initiative    

                                                             

The Dengue Vaccine Initiative is an international consortium of the International Vaccine Institute, the World Health Organization Initiative for Vaccine Research, the International Vaccine Access Center at the Johns Hopkins University Bloomberg School of Public Health and the Sabin Vaccine Institute that specializes in research, health economics, policy and advocacy to equip countries with objective information and scientific evidence to fight dengue fever. The Initiative is supported with funding by the Bill & Melinda Gates Foundation.

Media Contact

Rebecca Van Roy

Rebecca.vanroy@sabin.org

+1 (202) 683-1880

Follow us @preventdengue and like our Facebook page to receive more dengue updates and vaccine developments.

© 2016 Dengue Vaccine Initiative (via Sabin Vaccine Institute)

All rights reserved.

unsubscribe from this list    update subscription preferences

Republicado por:RM Consult